title: A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes.
abstract: The aim of this study was to determine the relation between the G/G genotype of a resistin gene promoter single nucleotide polymorphism (SNP) at -420 (rs1862513) and glycemic control by pioglitazone in type 2 diabetes. In Study 1, 121 type 2 diabetic patients were treated with pioglitazone (15 or 30 mg/day) for 12 weeks, in addition to previous medication. In Study 2, 63 patients who had been treated with pioglitazone for 12 weeks were examined retrospectively. In Study 1, multiple regression analysis revealed that the G/G but not C/G genotype was correlated with a reduction in fasting plasma glucose (FPG) and homeostasis model assessment of insulin resistance (HOMA-IR) compared to C/C. When adjusted for age, gender, and BMI, the G/G genotype was an independent factor for the reduction of FPG (P=0.020) and HOMA-IR (P =0.012). When studies 1 and 2 were combined by adjusting the studies, age, gender, and BMI, the reduction of HbA1c was correlated with the G/G genotype (beta=-0.511, P=0.044). Therefore, this pilot study suggests that the G/G genotype of resistin SNP -420 may be an independent predictor of the reduction of fasting plasma glucose and HOMA-IR by pioglitazone.
authors.affiliation: Institute of Diabetes Research Center, Takanoko Hospital, Ehime, Japan. hidemak@takanoko-hsp.jp
authors.forename: Hideichi
authors.initials: H
authors.lastname: Makino
authors.forename: Ikki
authors.initials: I
authors.lastname: Shimizu
authors.forename: Satoshi
authors.initials: S
authors.lastname: Murao
authors.forename: Shiori
authors.initials: S
authors.lastname: Kondo
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Tabara
authors.forename: Masao
authors.initials: M
authors.lastname: Fujiyama
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Fujii
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Takada
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Nakai
authors.forename: Kenichi
authors.initials: K
authors.lastname: Izumi
authors.forename: Jun
authors.initials: J
authors.lastname: Ohashi
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Kawamura
authors.forename: Junko
authors.initials: J
authors.lastname: Yamauchi
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Takata
authors.forename: Wataru
authors.initials: W
authors.lastname: Nishida
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Hashiramoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Onuma
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Osawa
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006706:Homeostasis / Q000187:drug effects; D006720:Homozygote; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics / Q000379:methods; D010865:Pilot Projects; D000077205:Pioglitazone; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics*; D052243:Resistin / Q000097:blood / Q000235:genetics*; D012189:Retrospective Studies; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D052243:Resistin; D045162:Thiazolidinediones; C517652:hemoglobin A1c protein, human